What is CCEL's last price and market cap on Chartloom?

The overview shows a last price near n/a and market cap near 0.04B (subject to data latency), alongside the price snapshot and profile on this page.

What P/E and 52-week range are shown for CCEL?

P/E (TTM) is n/a and 52-week range is $2.72 to $4.90 when available from the data feed; see the metrics and chart on this page.

Where do Chartloom’s CCEL figures come from?

Figures are compiled from market data and SEC-backed fundamentals used in the app. Use primary filings and a broker for trading decisions.

What trailing-twelve-month financials does Chartloom show for CCEL?

The company profile lists revenue (TTM) near $31M, net income (TTM) near $-247M, EPS (TTM) near $-0.31 when available from the market-data feed. Figures are informational and may lag live markets.

Does CCEL show a dividend on Chartloom?

The overview lists dividend per share (TTM) near $0.40 when those figures are present. Dividend history is compiled from vendor data, not a distribution notice.

Where is Cryo-Cell International Inc based, and what identifiers does Chartloom list?

The company context section lists headquarters in Oldsmar, Florida, US, 8.1M shares outstanding, ISIN US2288951088 when available from company profile and filing metadata.

Cryo-Cell International Inc

$CCEL

Health Care · Health Care Providers & Services

IR Run Scenarios

$4.29

-0.23%

Cryo-Cell International Inc

$CCEL

Health Care · Health Care Providers & Services

IR Run Scenarios

$4.29

-0.23%

Overview AI Summary Charts Financials Valuation

Profile

Read AI summary

Cryo-Cell International, Inc. is a cord blood bank, which engages in providing stem cell cryopreservation services and advancing regenerative medicine. The company is headquartered in Oldsmar, Florida and currently employs 72 full-time employees. The firm operates through three segments: cellular processing and cryogenic storage for family use, with a focus on the collection and preservation of umbilical cord blood and tissue stem cells; manufacture of PrepaCyte CB Processing System (PrepaCyte CB) units, the processing technology used to process umbilical cord blood stem cells, and cellular processing and cryogenic storage of umbilical cord blood stem cells for public use. The firm stores approximately 240,000 cord blood and cord tissue specimens. The specimens are stored in commercially available cryogenic storage units at its technologically and operationally advanced facility. The firm markets its cord blood stem cell preservation services directly to expectant parents and by distributing information through obstetricians, pediatricians, childbirth educators, certified nurse-midwives, and other related healthcare professionals.

Employees

72

Website

www.cryo-cell.com/

IPO

1994-04-04

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)

Net income (TTM)

EPS (TTM)

P/E (TTM)

P/S (TTM)

Forward P/E

Forward P/S

EV / EBITDA

PEG (TTM)

FCF yield (TTM)

Gross margin (TTM)

Net margin (TTM)

Forward revenue growth (NTM)

Dividend / share (TTM)

Dividend yield (TTM)

Payout ratio (TTM)

Dividend growth (5Y)

Company context

Exchange

NYSE MKT LLC

ISIN

US2288951088

Headquarters

Oldsmar, Florida, US

Shares outstanding

8.1M

NAICS sector

Health Care and Social Assistance

Institutional ownership

13.72%

Overview AI Summary Charts Financials Valuation

Profile

Read AI summary

Cryo-Cell International, Inc. is a cord blood bank, which engages in providing stem cell cryopreservation services and advancing regenerative medicine. The company is headquartered in Oldsmar, Florida and currently employs 72 full-time employees. The firm operates through three segments: cellular processing and cryogenic storage for family use, with a focus on the collection and preservation of umbilical cord blood and tissue stem cells; manufacture of PrepaCyte CB Processing System (PrepaCyte CB) units, the processing technology used to process umbilical cord blood stem cells, and cellular processing and cryogenic storage of umbilical cord blood stem cells for public use. The firm stores approximately 240,000 cord blood and cord tissue specimens. The specimens are stored in commercially available cryogenic storage units at its technologically and operationally advanced facility. The firm markets its cord blood stem cell preservation services directly to expectant parents and by distributing information through obstetricians, pediatricians, childbirth educators, certified nurse-midwives, and other related healthcare professionals.

Employees

72

Website

www.cryo-cell.com/

IPO

1994-04-04

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)